VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CRBU
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CRBUCaribou Biosciences, Inc.
$0.34$34M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
CRBU logo

Caribou Biosciences, Inc.

CRBU
NASDAQ · Cell & Gene Therapy
$0.34
At close - Nov 17, 4:00 PM EST - USD
Market Cap$34M
P/E-0.4x
52W High$2.49
Volume2.56M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Persistent Clinical Burn Threatens Capital Runway Stability

Caribou Biosciences faces a critical liquidity inflection point as its chRDNA platform development continues to outpace its ability to generate sustainable, non-milestone-dependent revenue.

GrowthMixed
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

CRBU price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

9/12 Beats

EPS beat 9 of last 12 quarters

02

Valuation risk

-101% Peers

P/E is 101% below peer median

03

Market leadership

RS 3 · Lag

Laggard (Underperforming 97% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 5

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
CRBU-78.57%
S&P 500 (^GSPC)+7.21%
1-Year Return
CRBU-81.97%
S&P 500 (^GSPC)+10.03%
3-Year Return
CRBU-93.47%
S&P 500 (^GSPC)+55.00%
5-Year Return
CRBU-98.47%
S&P 500 (^GSPC)+52.27%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$11M+11.7% YoY
Net income FY25
-$148M+0.7% YoY
Free cash flow FY25
-$112M+22.4% YoY
Operating margin FY25
-1220.5%+446.7 pts YoY
ROIC (FY25)-51%
Avg ROIC 5Y-50%
ROE (TTM)-102.7%
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate9/12 (75%)
Revenue Beat Rate8/12 (67%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 5, 2026
-$0.25+7.4%
vs -$0.27
$2M+0.8%
vs $2M
Q3 2026
Aug 13, 2026
-$0.24+25.9%
vs -$0.32
$1M-34.2%
vs $2M
Q2 2026
May 7, 2026
-$0.26+21.2%
vs -$0.33
$2M+8.3%
vs $2M
Q2 2026
Mar 5, 2026
-$0.28+15.2%
vs -$0.33
$4M+78.6%
vs $2M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Zacks Investment Research·6d ago
Caribou Biosciences (CRBU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Caribou Biosciences (CRBU) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Investment Research·Nov 5, 2026
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Beats Revenue Estimates

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.3 per share a year ago.

GlobeNewsWire·Nov 5, 2026
Caribou Biosciences Reports Third Quarter 2026 Financial Results

BERKELEY, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU) today reported financial results for the third quarter of 2026.

Zacks Investment Research·Nov 4, 2026
Caribou Biosciences, Inc. (CRBU) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Caribou Biosciences (CRBU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Filtered for Caribou Biosciences, Inc.More Headlines
04

Compare before deciding

Benchmark CRBU against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Caribou Biosciences, Inc. (CRBU)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
CRBU logoCRBUCaribou Biosciences, Inc.Current
$0.34$33.79M-0.3611.66%-1085%-102.74%—
EDIT logoEDITEditas Medicine, Inc.
$1.83$280.07M-3.8825.39%-144.95%-130.43%—
BEAM logoBEAMBeam Therapeutics Inc.
$20.65$2.12B-20.19120.01%-73.04%-9.69%—
NTLA logoNTLAIntellia Therapeutics, Inc.
$9.78$1.1B-3.2216.92%-805.75%-64.73%—
CRSP logoCRSPCRISPR Therapeutics AG
$40.15$3.87B-8.52-89.97%-1812.07%-25.59%—
FATE logoFATEFate Therapeutics, Inc.
$1.02$118.89M-1.01-51.24%-2619.64%-73.92%—

Compare CRBU vs Peers

Caribou Biosciences, Inc. (CRBU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs EDIT

Most directly comparable listed peer for CRBU.

Scale Benchmark

vs TMO

Larger-name benchmark to compare CRBU against a more recognizable public peer.

Peer Set

Compare Top 5

vs EDIT, BEAM, NTLA, CRSP

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

CRBU SEC Filings & Documents

Caribou Biosciences, Inc. (CRBU) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 5, 2026·SEC

Material company update

Aug 13, 2026·SEC

Material company update

Jun 18, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 5, 2026·SEC

FY 2025

Mar 10, 2025·SEC

FY 2024

Mar 11, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 5, 2026·SEC

FY 2026

Aug 13, 2026·SEC

FY 2026

May 7, 2026·SEC

Get notified when CRBU posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

CRBU Frequently Asked Questions

Caribou Biosciences, Inc. (CRBU) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Caribou Biosciences, Inc.'s revenue?

Caribou Biosciences, Inc. (CRBU) reported $9.4M in revenue over the trailing twelve months. Revenue was $11.2M in fiscal year 2025. That is 93% more than the $5.8M of fiscal year 2019.

How fast is Caribou Biosciences, Inc. growing?

Caribou Biosciences, Inc. (CRBU) grew revenue by 1.6% over the trailing twelve months, compared with the twelve months before.

Is CRBU profitable?

No. Caribou Biosciences, Inc. (CRBU) reported a net loss of $102.5M over the trailing twelve months.

Dividend & Returns
What is CRBU's return on equity?

Caribou Biosciences, Inc. (CRBU) had a return on equity (ROE) of -102.7% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Caribou Biosciences, Inc.'s free cash flow?

Caribou Biosciences, Inc. (CRBU) had negative free cash flow of $93.0M over the trailing twelve months.

What if you invested $1,000 in CRBU back in 2019?

Total return calculator · dividends reinvested · 7+ years of data

See returns →